Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2022 Earnings Conference Call March 2, 2023 5:00 PM ET Company Participants Carrie Siragusa – Executive Director, Corporate Strategy and Investor Relations Lonnel Coats – Chief Executive Officer Jeff Wade – President and Chief Financial Officer Craig Granowitz – Senior Vice President and Chief Medical Officer Conference Call Participants Yasmeen Rahimi – Piper Sandler Carly Kenselaar – Citi Joseph Stringer – Needham & Company Operator Good afternoon, and welcom ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 76-0 ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2022 Earnings Conference Call November 9, 2022 5:00 PM ET Company Participants Mike Kelly – Investor Relations Lonnel Coats – Chief Executive Officer Jeff Wade – President and Chief Financial Officer Craig Granowitz – Senior Vice President and Chief Medical Officer Conference Call Participants Carly Kenselaar – Citigroup Yasmeen Rahimi – Piper Sandler Joseph Stringer – Needham & Company Operator Good day, ladies and gentlemen. Welcome to the Lexicon Pharmaceuti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) (Sta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q2 2022 Earnings Conference Call August 2, 2022 5:00 PM ET Company Participants Mike Kelly - Investor Relations Lonnel Coats - Chief Executive Officer Jeff Wade - President & Chief Financial Officer Craig Granowitz - Senior Vice President & Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Joseph Stringer - Needham & Company Operator Good afternoon, ladies and gentlemen and welcome to the Lexicon Pharmaceuticals Inc. Second Quarter 2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) (State o ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2022 Results Conference Call May 5, 2022 8:00 AM ET Company Participants Charles Schultz - Investor Relations Lonnel Coats - President and Chief Executive Officer Jeffrey Wade - President and Chief Financial Officer Craig Granowitz - Senior Vice President and Chief Medical Officer Conference Call Participants Jessica Fye - JP Morgan Joseph Stringer - Needham & Company Operator Good morning. This is Jesse, and I will be your conference operator today. At this ti ...

(Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 or UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) (State or Oth ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2021 Earnings Conference Call February 28, 2022 8:00 AM ET Company Participants Chas Schultz - Executive Director, Corporate Communications and Investor Relations Lonnel Coats - Chief Executive Officer Jeff Wade - President and Chief Financial Officer Craig Granowitz - Senior Vice President and Chief Medical Officer Conference Call Participants Joseph Stringer - Needham Julian Harrison - BTIG Disclaimer*: This transcript is designed to be used alongside the fre ...